Bloomberg Law spoke to Member Theresa Carnegie in an article discussing how four leading drugmakers are challenging the Medicare Drug Price Negotiation Program in federal court. Theresa comments on the situation between the drug manufacturers and the government highlighting the difficult position for manufacturers who must choose between complying with the program or losing access to all other federal health programs.

Theresa said, “It really is not a viable option for the manufacturers to not sell their products to Medicare and the government would certainly not want that outcome in terms of patient access to medications.”

Source

Bloomberg Law